Latest

cytokine storm

·October 5, 2022·7 min read

A Possible Brain Mechanisms Behind COVID-19 Delirium

Brain cells exposed to blood taken from COVID-19 patients with delirium showed a decrease in neurogenesis and an increase in cell death. The findings also indicate a key role for cytokines produced in the immune system during infection and shed light on the molecular mechanisms of COVID-19 related delirium.

Featured Neuroscience

·November 16, 2021·4 min read

Neuroimmune Interactions and Brain Plasticity

Researchers examine how neuroimmune interactions promote brain plasticity and shed new light on how neuroimmune activity may have implications for a range of disorders, including neurological changes experienced by COVID-19 survivors.

This shows a body made up of chemical elements

Featured Neurology Neuroscience

·February 24, 2021·5 min read

Botulinum Toxin for Novel Therapeutics

Genetically engineering botulinum toxin could help advance new treatments for everything from neurodegenerative disorders to cytokine storms.

This shows someone being poked with acupuncture needles

Featured Neurology

·August 12, 2020·7 min read

Electroacupuncture Activates Inflammation-Regulating Pathways and Tames Cytokine Storm

Using electroacupuncture, researchers stimulated the vagus-adrenal axis to induce secretion of dopamine from chromaffin cells in the adrenal glands. Mice exposed to this treatment had lower levels of three types of inflammation-inducing cytokines and improved survival chances over those who did not receive electroacupuncture. Animals treated with the method immediately before they developed cytokine storms experienced lower levels of inflammation during their disease and an increase in survival odds from 20% to 80%.

Featured Genetics Neurology Neuroscience

·May 26, 2020·2 min read

Researchers flag similarities between COVID-19 deaths and severe rheumatic illnesses

After natural killer immune cells kill virus-infected cells, T and B immune cells produce cytokines. This makes the immune reaction stronger and results in the cytokine storm associated with severe COVID-19 infection.

Featured Neuroscience

·May 24, 2020·5 min read

Preventing ‘cytokine storm’ may ease severe COVID-19 symptoms

Treating coronavirus patients with alpha-blockers may help prevent the cytokine storm associated with severe COVID-19 infection. Alpha-blockers interfere with the cell signaling that triggers cytokine storms. Mice with bacterial infections that were treated with alpha-blockers experienced reduced cytokine storms and decreased death rates.

Featured Neuroscience Open Neuroscience Articles

·May 20, 2020·3 min read

COVID-19 cytokine storm: Possible mechanism for the deadly respiratory syndrome

SARS-CoV-2, the virus responsible for COVID-19, enters human cells by attaching to ACE2 and utilizing TMPRSS2. Drugs that block ACE2 or inhibit the enzyme could help treat the coronavirus, but only during early infection. As the infection progresses, SARS-CoV-2 becomes engulfed in human cells, reducing the number of ACE2 receptors on a cell and leading to an increase of angiotensin II in the blood. Angiotensin II triggers an inflammatory pathway, providing a positive feedback cycle, named IL-6 amplifier, resulting in excessive immune activation and the cytokine storm associated with severe COVID-19.

This shows someone holding a box of actemra

Featured Neurology Neuroscience

·May 3, 2020·2 min read

Arthritis Drug Presents Promise as Treatment for COVID-19 Pneumonia

UCSD has launched a Phase III clinical trial to assess whether tocilizumab (Actemra), a drug commonly prescribed for rheumatoid arthritis and other inflammatory disorders, has therapeutic value for those at risk of developing severe COVID-19 infection. The drug is a monoclonal antibody-based therapy that blocks receptors for interleukin-6, a cytokine that triggers inflammation as an early immune response to coronavirus. Blocking IL-6 could prevent the risk of the COVID-19 associated cytokine storm many with severe infection experience.

Featured Genetics Neuroscience

·April 24, 2020·3 min read

Asthma drug in clinical trial to treat severe COVID-19 patients

A new clinical trial is underway to test ibudilast, an asthma drug approved in Japan, for the treatment of severe COVID-19. Ibudilast is a MIF inhibitor. MIF is a gene that regulates immune response and is a driver of inflammation which results in the cytokine storm associated with coronavirus.

Featured Genetics Neuroscience

·April 16, 2020·3 min read

Proteins may halt the severe cytokine storms seen in COVID-19 patients

Researchers have designed antibody-like receptor proteins that can bind to cytokines, possibly reducing the effects of the COVID-19 associated cytokine storm.